NVO logo

NVO Novo Nordisk A/S

New York Stock Exchange · Drug Manufacturers - General · Healthcare

$38.77
-0.10 (-0.27%)

Novo Nordisk A/S operates as a global healthcare enterprise, dedicated to the innovation, development, production, and commercialization of pharmaceutical solutions. Its business is primarily divided into two key segments: Diabetes and Obesity Care, and Rare Disease. The Diabetes and Obesity Care segment offers a comprehensive portfolio of treatments for diabetes (including insulins, GLP-1 analogu…

Market Cap: $173.46Bwww.novonordisk.com

Price

$39.62-18.58%
$37.32$41.10$44.88$48.66
Aug 25Nov 18

Social Signal Score

47
5d
54
3 mentions
-2.7%
30d
51
30 mentions
+1.5%
60d
45
61 mentions
+3.8%
90d
39
109 mentions
-15.6%
news: 109

Analyst Ratings

39 analysts
Buyconsensus
Strong Buy 1Buy 22Hold 13Sell 3Strong Sell 0
Avg price target$42.33+9.2%
Low $40Median $40High $47
Current Consensus

52-week range

$35.29$63.98
Last close
$39.62
Off 52w high
-38.1%
200-day average
$42.95
vs 200-day
-7.8%

Compare with other stocks off their highs

Revenue

$79.19B+167.80%
$26.61B$50.02B$73.42B$96.82B
Dec 2016Sep 2026

Analyst Estimates

FY2025
$23.54
$23.21–$23.80
7 analysts
FY2026
$23.03-2% YoY
$21.94–$24.73
7 analysts
FY2027
$22.69-1% YoY
$21.50–$23.61
8 analysts

Consensus estimates, not results. Via Financial Modeling Prep.

Company Profile

CEO
Maziar Mike Doustdar
Sector
Healthcare
Industry
Drug Manufacturers - General
Employees
68,794
Beta
0.35
Country
DK
Piotroski score
7 / 9 (Strong)
Altman Z-score
3.66
www.novonordisk.com